Alexander M.A. van der Wiel, Victoria Jackson Patel, Raymon Niemans, Ala Yaromina, Emily Liu, Damiënne Marcus, Alexandra M. Mowday, Natasja G. Lieuwes, Rianne Biemans, Xiaojing Lin, Zhe Fu, Sisira Kumara, Arthur Jochems, Amir Ashoorzadeh, Robert F. Anderson, Kevin O. Hicks, Matthew R. Bull, Maria R. Abbattista, Christopher P. Guise, Sofie Deschoemaeker, Sophie Thiolloy, Arne Heyerick, MorwenaJ. Solivio, Silvia Balbo, Jeff B. Smaill, Jan Theys, Ludwig J. Dubois, Adam V. Patterson and Philippe Lambin have published a paper entitled, ‘Selectively targeting Tumor Hypoxia with the Hypoxia-Activated Prodrug CP-506’.
Hypoxia-activated prodrugs (HAP) are a promising class of antineoplastic agents that can selectively eliminate hypoxic tumor cells. This study evaluates the hypoxia-selectivity and antitumor activity of CP-506, a DNA alkylating HAP with favorable pharmacologic properties.
In vivo, the antitumor effects of CP-506 were selective for hypoxic tumor cells and causally related to tumor oxygenation. Our results demonstrate that CP-506 selectively targets hypoxic tumor cells and has broad antitumor activity.
Read the paper
CP-506 was discovered by ACSRC scientists and is now entering human clinical trials.
Review the clinical trial